RET protein expression in papillary renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 900-905

  Flavin, Richard ^a,c,d   Finn, Stephen P ^a,d   Choueiri, Toni K ^d   Ingoldsby, Helen ^c   Ring, Martina ^b   Barrett, Ciara ^a   Rogers, Miranda ^d   Smyth, Paul ^a   O'Regan, Esther ^a   Gaffney, Eoin ^a   O'Leary, John J ^a,b   Loda, Massimo ^d,e   Signoretti, Sabina ^e   Sheils, Orla ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b Pathology Research Laboratory   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

GDNF; Papillary renal cell carcinoma; RET

Indexed keywords

PROTEIN RET;

ADULT; ARTICLE; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; ONCOCYTOMA; PAPILLARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; SURVIVAL;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-RET; TUMOR MARKERS, BIOLOGICAL;

EID: 84870541455     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.025     Document Type: Article

References (40)

1. Eble J.N., Sauter G., Epstein J.I., et al. Pathology and genetics of tumors of the urinary system and male genital organs 2004, IARC Press, Lyon.
2. Storkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:987-989.
3. Kovacs G., Akhtar M., Beckwith B.J., et al. The Heidelberg classification of renal cell tumors. J Pathol 1997, 183:131-133.
4. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
5. Delahunt B., Eble J.N. Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997, 10:537-544.
6. Mejean A., Hopirtean V., Bazin J.P., et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: Meaning of histological typing and multifocality. J Urol 2003, 170:764-767.
7. Ishizaka Y., Itoh F., Tahira T., et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989, 4:1519-1521.
8. Iwamoto T., Taniguchi M., Asai N., et al. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993, 8:1087-1091.
9. Takahashi M., Buma Y., Hiai H. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 1989, 4:805-806.
10. Takahashi M., Buma Y., Iwamoto T., et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988, 3:571-578.
11. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001, 12:361-373.
12. Manie S., Santoro M., Fusco A., et al. The RET receptor: Function in development and dysfunction in congenital malformation. Trends Genet 2001, 17:580-589.
13. Airaksinen M.S., Saarma M. The GDNF family: Signaling, biological functions, and therapeutic value. Nat Rev Neurosci 2002, 3:383-394.
14. Asa S.L. How familial cancer genes and environmentally induced oncogenes have changed the endocrine landscape. Mod Pathol 2001, 14:246-253.
15. Jhiang S.M. The RET proto-oncogene in human cancers. Oncogene 2000, 19:5590-5597.
16. Romeo G., Ronchetto P., Luo Y., et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:377-378.
17. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60(4):557-563.
18. Santoro M., Carlomagno F., Hay I.D., et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992, 89:1517-1522.
19. Fluge O., Haugen D.R., Akslen L.A., et al. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene 2001, 20:885-892.
20. Kjellman P., Learoyd D.L., Messina M., et al. Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg 2001, 88:557-563.
21. Mai K.T., Landry D.C., Thomas J., et al. Ret oncogene protein expression in papillary thyroid carcinoma and related lesions. Tumori 2001, 87:166-172.
22. Cheung C.C., Ezzat S., Freeman J.L., et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001, 14:338-342.
23. Rebelo S., Domingues R., Catarino A.L., et al. Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma. Int J Oncol 2003, 23:1025-1032.
24. Nisolle M., Gillerot S., Casanas-Roux F., et al. Immunohistochemical study of the proliferation index, estrogen receptors, and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999, 14:2844-2850.
25. Boulay A., Breuleux M., Stephan C., et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer. Cancer Res 2008, 68:3743-3751.
26. Ceyhan G.O., Giese N.A., Erkan M., et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 2006, 244:274-281.
27. Sawai H., Okada Y., Kazanjian K., et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005, 65:11536-11544.
28. Thomas R.K., Baker A.C., Debiasi R.M., et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351.
29. Cheung C.C., Ezzat S., Ramyar L., et al. Molecular basis off Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:878-882.
30. Chiappetta G., Toti P., Cetta F., et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 2002, 87:364-369.
31. Musholt P.B., Imkamp F., von Wasielewski R., et al. RET rearrangements in archival oxyphilic thyroid tumors: New insights in tumorigenesis and classification of Hurthle cell carcinomas?. Surgery 2003, 134:881-889. Discussion 889.
32. Kim D., Dressler G.R. PTEN modulates GDNF/RET mediated chemotaxis and branching morphogenesis in the developing kidney. Dev Biol 2007, 307:290-299.
33. Kondo K., Yao M., Kobayashi K., et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001, 91:219-224.
34. He L., Fan C., Gillis A., et al. Coexistence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta 2007, 1772:1134-1142.
35. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
36. Cassinelli G., Favini E., Degl'Innocenti D., et al. RET/PTC1-driven neoplastic transformation and pro-invasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 2009, 11:10-21.
37. Jeffers M., Schmidt L., Nakaigawa N., et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997, 94:11445-11450.
38. Salvi A., Marchina E., Benetti A., et al. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 2008, 33:271-276.
39. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343-2350.
40. Plaza-Menacho I., Mologni L., Sala E., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007, 282:29230-29240.